The 2025 AACE Dyslipidemia Guidelines – Cost concerns over evidence and missing the target?

Key Points

• Cost considerations are significant, impacting the implementation of dyslipidemia guidelines and patient outcomes.
• Key evidence suggests that the proposed guidelines may not optimize clinical outcomes for all patients.
• Analysis of the guidelines reveals gaps in risk assessment and cost-effectiveness strategies without clear metrics.
• While the guidelines may improve management, they could also result in increased costs without guaranteed benefits.